Premarket decoded — Sept 22 🎰 Three stories explain 80% of this tape: 1. $CLDX -37% on POSITIVE Phase 3 data 📉 Barzolvolimab hit all endpoints in CSU — 42–4

Premarket decoded — Sept 22 🎰 Three stories explain 80% of this tape: 1. $CLDX -37% on POSITIVE Phase 3 data 📉 Barzolvolimab hit all endpoints in CSU — 42–46% complete response vs ~10% placebo, FDA filing 2027. Stock STILL halved. Why? +40% run-up into the readout. The bar was perfection. Biotec…